[Management of submacular hemorrhage : What, when, how?]
Therapie subretinaler Makulablutungen : Was, wann, wie?
Age-related macular degeneration
Functional result
Intravitreal treatment
Minimally invasive procedures
Vascular endothelial growth factor inhibitors
Journal
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
ISSN: 1433-0423
Titre abrégé: Ophthalmologe
Pays: Germany
ID NLM: 9206148
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
9
8
2020
medline:
21
10
2020
entrez:
9
8
2020
Statut:
ppublish
Résumé
Subretinal hemorrhage involving the macula is a typical complication in a variety of retinal diseases, whereby age-related macular degeneration (AMD) is by far the leading cause. A literature search was carried out in PubMed. Numerous studies have demonstrated the effectiveness of various approaches to the management of submacular hemorrhage, including intravitreal anti-VEGF treatment, pneumatic displacement supported by fibrinolytic agents or surgical drainage. There is currently no consensus regarding evidence-based standard treatment for macular hemorrhage, although there is a trend towards minimally invasive approaches. Regardless of the choice of the primary treatment approach, the time to treatment and an accompanying intravitreal treatment with VEGF inhibitors are decisive for the functional outcome. HINTERGRUND: Subretinale Blutungen im Bereich der Makula sind eine typische Komplikation verschiedener retinaler Erkrankungen, wobei die exsudative altersbedingte Makuladegeneration (AMD) die bei Weitem häufigste Ursache darstellt. Es erfolgte eine Literaturrecherche über PubMed. Zahlreiche Studien zur Behandlung submakulärer Blutungen zeigen, dass eine erfolgreiche morphologische und funktionelle Behandlung mit unterschiedlichen Ansätzen wie der intravitrealen Gabe von VEGF(„vascular endothelial growth factor“)-Inhibitoren, der durch Fibrinolytika unterstützten pneumatischen Dislokation oder der chirurgischen Drainage möglich ist. Aus den vorliegenden Daten kann bis heute kein genereller evidenzbasierter Therapiestandard abgeleitet werden, wobei sich ein zunehmender Trend zur Anwendung minimal-invasiver Verfahren abzeichnet. Unabhängig von der Wahl des initialen Therapieverfahrens sind eine möglichst frühzeitige Intervention sowie eine begleitende intravitreale Behandlung mit VEGF-Inhibitoren für das funktionelle Ergebnis entscheidend.
Sections du résumé
BACKGROUND
BACKGROUND
Subretinal hemorrhage involving the macula is a typical complication in a variety of retinal diseases, whereby age-related macular degeneration (AMD) is by far the leading cause.
METHOD
METHODS
A literature search was carried out in PubMed.
RESULTS
RESULTS
Numerous studies have demonstrated the effectiveness of various approaches to the management of submacular hemorrhage, including intravitreal anti-VEGF treatment, pneumatic displacement supported by fibrinolytic agents or surgical drainage.
DISCUSSION
CONCLUSIONS
There is currently no consensus regarding evidence-based standard treatment for macular hemorrhage, although there is a trend towards minimally invasive approaches. Regardless of the choice of the primary treatment approach, the time to treatment and an accompanying intravitreal treatment with VEGF inhibitors are decisive for the functional outcome.
ZUSAMMENFASSUNG
UNASSIGNED
HINTERGRUND: Subretinale Blutungen im Bereich der Makula sind eine typische Komplikation verschiedener retinaler Erkrankungen, wobei die exsudative altersbedingte Makuladegeneration (AMD) die bei Weitem häufigste Ursache darstellt.
METHODEN
METHODS
Es erfolgte eine Literaturrecherche über PubMed.
ERGEBNISSE
UNASSIGNED
Zahlreiche Studien zur Behandlung submakulärer Blutungen zeigen, dass eine erfolgreiche morphologische und funktionelle Behandlung mit unterschiedlichen Ansätzen wie der intravitrealen Gabe von VEGF(„vascular endothelial growth factor“)-Inhibitoren, der durch Fibrinolytika unterstützten pneumatischen Dislokation oder der chirurgischen Drainage möglich ist.
DISKUSSION
CONCLUSIONS
Aus den vorliegenden Daten kann bis heute kein genereller evidenzbasierter Therapiestandard abgeleitet werden, wobei sich ein zunehmender Trend zur Anwendung minimal-invasiver Verfahren abzeichnet. Unabhängig von der Wahl des initialen Therapieverfahrens sind eine möglichst frühzeitige Intervention sowie eine begleitende intravitreale Behandlung mit VEGF-Inhibitoren für das funktionelle Ergebnis entscheidend.
Autres résumés
Type: Publisher
(ger)
HINTERGRUND: Subretinale Blutungen im Bereich der Makula sind eine typische Komplikation verschiedener retinaler Erkrankungen, wobei die exsudative altersbedingte Makuladegeneration (AMD) die bei Weitem häufigste Ursache darstellt.
Identifiants
pubmed: 32767098
doi: 10.1007/s00347-020-01192-5
pii: 10.1007/s00347-020-01192-5
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
848-857Références
Avery RL, Fekrat S, Hawkins BS et al (1996) Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16:183–189
pubmed: 8789855
Hochman MA, Seery CM, Zarbin MA (1997) Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol 42:195–213
pubmed: 9406367
Glatt H, Machemer R (1982) Experimental subretinal hemorrhage in rabbits. Ophthalmology 94:762–773
Lewis H, Resnick SC, Flannery JG et al (1991) Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 111:197–204
pubmed: 1899537
Bennett SR, Folk JC, Blodi CF et al (1990) Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 109:33–37
pubmed: 2297030
Berrocal MH, Lewis ML, Flynn HW Jr (1996) Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol 122:486–493
pubmed: 8862044
Scupola A, Coscas G, Soubrane G, Balestrazzi E (1999) Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 213:97–102
pubmed: 9885385
Hassan AS, Johnson MW, Schneiderman TE et al (1999) Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 106:1900–1906
pubmed: 10519583
Hattenbach LO, Brieden M, Koch F et al (2002) Intravitreal injection of rt-PA and gas in the management of minor submacular haemorrhages secondary to age-related macular degeneration. Klin Monbl Augenheilkd 219:512–518
pubmed: 12195317
Hattenbach LO, Klais C, Koch FHJ et al (2001) Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology 108:1485–1492
pubmed: 11470706
Heriot WJ (1996) Intravitreal gas and tPA: an outpatient procedure for submacular hemorrhage. In: Vail vitrectomy meeting Vail, Colorado, 10–15 March 1996
Hesse L, Schmidt J, Kroll P (1999) Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 237:273–277
pubmed: 10208258
Hesse L, Schroeder B, Heller G et al (2000) Quantitative effect of intravitreally injected tissue plasminogen activator and gas on subretinal hemorrhage. Retina 20:500–505
pubmed: 11039425
Coll GE, Sparrow JR, Marinovic A et al (1995) Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 15:319–326
pubmed: 8545578
Takeuchi A, Kricorian G, Yao XY et al (1994) The rate and source of albumin entry into saline-filled experimental retinal detachments. Invest Ophthalmol Vis Sci 35:3792–3798
pubmed: 7928176
Ohji M, Saito Y, Hayashi A et al (1998) Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 116:1326–1332
pubmed: 9790631
Tsuyama T, Hirose H, Hattori T (2016) Intravitreal tPA injection and pneumatic displacement for submacular hemorrhage in a 10-year-old child. Case Rep Ophthalmol Med 2016:9809583
pubmed: 27722001
pmcid: 5045984
Lee K, Park YG, Park YH (2020) Visual prognosis after pneumatic displacement of submacular hemorrhage according to age-related macular degeneration subtypes. Retina. https://doi.org/10.1097/IAE.0000000000002762
pubmed: 32833786
doi: 10.1097/IAE.0000000000002762
Sniatecki JJ, Ho-Yen G, Clarke B et al (2019) Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration. Eur J Ophthalmol. https://doi.org/10.1177/1120672119891625
pubmed: 31813290
doi: 10.1177/1120672119891625
Adrean SD, Chaili S, Pirouz A et al (2019) Rapid displacement of subretinal hemorrhage from a choroidal neovascular membrane with intravitreal C3F8 gas and face-down positioning. Am J Ophthalmol Case Rep 14:79–82
pubmed: 30949612
pmcid: 6428934
Kobayashi T, Fukumoto M, Takai N, Maruyamac K, Tada R, Shouda H, Kida T, Ikeda T (2020) A case of pneumatic displacement with gas tamponade performed for macular subretinal hemorrhage complicating Vogt-Koyanagi-Harada disease. Case Rep Ophthalmol 11:143–150
pubmed: 32308616
pmcid: 7154246
Maggio E, Peroglio Deiro A, Mete M et al (2020) Intravitreal recombinant tissue plasminogen activator and sulphur hexafluoride gas for submacular hemorrhage displacement in age-related macular degeneration: looking behind the blood. Ophthalmologica. https://doi.org/10.1159/000505752
pubmed: 31940651
doi: 10.1159/000505752
Hrach CJ, Johnson MW, Hassan AS et al (2000) Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol 118:659–663
pubmed: 10815158
Johnson MW, Olsen KR, Hernandez E (1991) Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina 11:250–258
pubmed: 1925092
McAllister IL, Chen SD, Patel JI et al (2010) Management of submacular haemorrhage in age-related macular degeneration with intravitreal tenecteplase. Br J Ophthalmol 94(2):260–261
pubmed: 20139293
Lee JP, Park JS, Kwon OW et al (2016) Management of acute submacular hemorrhage with intravitreal injection of tenecteplase, anti-vascular endothelial growth factor and gas. Korean J Ophthalmol 30(3):192–197
pubmed: 27247518
pmcid: 4878979
Hillenkamp J, Surguch V, Framme C et al (2010) Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 248(1):5–11
pubmed: 19669780
Sharei V, Höhn F, Köhler T et al (2010) Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 20(1):174–179
pubmed: 19927267
Koss MJ, Scholtz S, Haeussler-Sinangin Y et al (2010) Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration. Ophthalmologica 224(2):72–78
pubmed: 19707030
Ritzau-Tondrow U, Baraki H, Hoerauf H (2012) Minimally invasive therapy of submacular hemorrhage in exsudative age-related macular degeneration. Ophthalmologe 109(7):670–675
pubmed: 22752626
Klettner A, Grotelüschen S, Treumer F et al (2015) Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol 99(6):864–869
pubmed: 25740806
Klettner A, Puls S, Treumer F (2012) Compatibility of recombinant tissue plasminogen activator and bevacizumab co-applied for neovascular age-related macular degeneration with submacular hemorrhage. Arch Ophthalmol 130(7):875–881
pubmed: 22410628
Meyer CH, Scholl HP, Eter N et al (2008) Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 86(5):490–494
pubmed: 18221499
de Jong JH, van Zeeburg EJ, Cereda MG et al (2016) Intravitreal versus subretinal administration of recombinant tissue plasminogen avtivator combined with gas for acute submacular hemorrhages due to age-related macular degeneration: an exploratory prospective study. Retina 36(5):914–925
pubmed: 26807631
Boyer DS, Antoszyk AN, Awh CC, MARINA Study Group et al (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114(2):246–252
pubmed: 17270674
Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65 (ANCHOR Study Group)
pubmed: 19118696
Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431
pubmed: 17021318
Wolf S, Holz FG, Korobelnik JF et al (2011) Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. Br J Ophthalmol 95(12):1713–1718
pubmed: 21951567
Ying GS, Maguire MG, Daniel E et al (2016) Comparison of age-related macular degeneration treatments trials research group. Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials. Ophthalmology 123(2):352–360
pubmed: 26545320
Altaweel MM, Daniel E, Martin DF et al (2015) Outcomes of eyes with lesions composed of >50 % blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology 122(2):391–398
pubmed: 25307130
Shin JY, Lee JM, Byeon SH (2015) Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage. Am J Ophthalmol 159(5):904–914
pubmed: 25637179
Höhn F, Mirshahi A, Hattenbach LO (2010) Combined intravitreal injection of bevacizumab and SF6 gas for treatment of submacular hemorrhage secondary to age-related macular degeneration. Ophthalmologe 107(4):328–332
pubmed: 19669150
Vander JF, Federman JL, Greven C et al (1991) Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmology 98:23–27
pubmed: 2023727
de Juan E Jr, Machemer R (1988) Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 105:25–29
pubmed: 3337190
Ibanez HE, Williams DF, Thomas MA et al (1995) Surgical management of submacular hemorrhage. Arch Ophthalmol 113:62–69
pubmed: 7826295
Wilkins CS, Mehta N, Wu CY et al (2020) Outcomes of pars plana vitrectomy with subretinal tissue plasminogen activator injection and pneumatic displacement of fovea-involving submacular haemorrhage. BMJ Open Ophthalmol 5:e394
pubmed: 32201733
pmcid: 7076260
Hillenkamp J, Klettner A, Puls S et al (2012) Subretinal co-application of rtPA and bevacizumab for exudative AMD with submacular hemorrhage. Compatibility and clinical long-term results. Ophthalmologe 109(7):648–656
pubmed: 22752624
Kadonosono K, Arakawa A, Yamane S (2015) Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air. Ophthalmology 122(1):123–128
pubmed: 25200400
Chang W, Garg SJ, Maturi R (2014) Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol 157(6):1250–1257
pubmed: 24531021
Oshima Y, Ohji M, Tano Y (2007) Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage. Br J Ophthalmol 91(2):193–198
pubmed: 16916872
Maier M, Hattenbach LO, Klein J et al (2020) Real-time optical coherence tomography-assisted high-precision vitreoretinal surgery in the clinical routine. Ophthalmologe 117(2):158–165
pubmed: 31728615
Peyman GA, Blinder KJ, Paris CL (1991) A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg 22(2):102–108
pubmed: 2038468
Cereda MG, Parolini B, Bellesini E (2010) Surgery for CNV and autologous choroidal RPE patch transplantation: exposing the submacular space. Graefes Arch Clin Exp Ophthalmol 248(1):37–47
pubmed: 19802629
Machemer R, Steinhorst UH (1993) Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 231:635–641
pubmed: 8258397
Pertile G, Claes C (2002) Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol 134(4):560–565
pubmed: 12383813
Eckardt C, Eckardt U, Conrad HG (1999) Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 237(4):313–325
pubmed: 10208265
Bopp S (2012) Subretinal hemorrhage. Natural course and staging. Ophthalmologe 109(7):635–643
pubmed: 22814923
Kuhli-Hattenbach C, Miesbach W, Scharrer I et al (2012) Massive subretinal hemorrhage and anticoagulants. An unfortunate combination? Ophthalmologe 109(7):665–669
pubmed: 22814925